The anti-CTLA-4 monoclonal antibody directed against the inhibitory receptor exempts the inhibitory effect of CTLA-4 activation, resulting in activation of T lymphocytes and thus the destruction of tumor cells. The gene discussed is CTLA4; the disease is neoplasm.